Thermo Fisher and Janssen to co-develop companion diagnostics for NSCLCMarch 13, 2020
Thermo Fisher Scientific has announced to develop a companion diagnostic (CDx) in oncology in collaboration with Janssen Biotech, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A companion diagnostic is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person
The CDx will support clinical trial enrollment globally, stated the company
According to the mutual agreement, Thermo Fisher Scientific will collaborate with scientists at the Janssen Research & Development, LLC to validate multiple biomarkers for use with Thermo Fisher’s Oncomine Dx Target Test. This will be used to identify variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer (NSCLC).
Oncomine Dx target test is a next-generation sequencing (NGS) assay that contains 46 cancer-related biomarkers and a workflow that features a fast turnaround time and the lowest sample requirements on the market for detection of both DNA and RNA variants.